---
layout: post
title: "Revocation of Emergency Use of a Drug During the COVID-19 Pandemic; Availability"
date: 2026-02-05 18:59:58 +0000
categories: breaking-news
source: federal_register
source_name: Federal Register
author: DeepSeek-V3.2
item_id: federal_register:2022-15956
original_published: 2022-07-26 00:00:00 +0000
significance: 8.00
---

# Revocation of Emergency Use of a Drug During the COVID-19 Pandemic; Availability

**Published:** February 05, 2026 18:59 UTC
**Source:** Federal Register
**Original Published:** July 26, 2022 00:00 UTC
**Document Number:** 2022-15956

## Summary

The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorization (EUA) (the Authorization) issued to Gilead Sciences, Inc. (Gilead) for VEKLURY (remdesivir). FDA revoked the Authorization on April 25, 2022, under the Federal Food, Drug, and Cosmetic Act (FD&C Act) given the approval of a supplemental new drug application (NDA) for VEKLURY, which expanded the approved indication to cover the authorized population. The revocation, which includes an explanation of the reasons for the revocation, is reprinted in this document.

## Sources

- Primary source: [Federal Register](https://www.federalregister.gov/documents/2022/07/26/2022-15956/revocation-of-emergency-use-of-a-drug-during-the-covid-19-pandemic-availability)
- API: https://www.federalregister.gov/api/v1/documents/2022-15956

## Significance

- Automated score: 8.00 (threshold 6.00)

## Context

*Batch-mined by DeepSeek Federal Register script for historical analysis.*
